SAB4200548
小鼠单克隆抗 IDH1 (R132H) 抗体
clone HMab-1, purified from hybridoma cell culture
别名:
可溶性抗 异柠檬酸脱氢酶 1 (NADP +), 抗 IDCD, 抗 IDH, 抗 IDP, 抗 IDPC, 抗 NADP (+) 特异性 ICDH, 抗 PICD, 抗 草酰琥珀酸脱羧酶, 胞质抗 NADP 依赖性异柠檬酸脱氢酶, 过氧化物酶体抗 NADP 依赖性异柠檬酸脱氢酶
产品名称
小鼠单克隆抗 IDH1 (R132H) 抗体, clone HMab-1, purified from hybridoma cell culture
biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
HMab-1, monoclonal
form
buffered aqueous solution
mol wt
antigen ~43 kDa
species reactivity
human
concentration
~1.0 mg/mL
technique(s)
western blot: 4.0-8.0 μg/mL using extract of HEK-293T cells overexpressing IDH1R132H.
UniProt accession no.
application(s)
research pathology
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... IDH1(3417)
Application
抗-IDH1（R132H）抗体用于：
- 免疫印迹
- 免疫组化
- 蛋白印迹
- 细胞周期分析和凋亡测定
- 染色质免疫沉淀（ChIP）测定
- 体外 迁移实验
Biochem/physiol Actions
异柠檬酸脱氢酶1（IDH1）将 NADP 作为共底物，催化异柠檬酸氧化脱羧成 α α -KG。IDH1 突变为 Arg132（R132）特有，这一突变使其具有生成2-羟基戊二酸（2HG）（而不是 α-KG）的功能。此产品通过影响 DNA 和组蛋白甲基化，改变基因转录。存在几种 IDH1 突变，包括 R132H、R132C、R132S、R132G 和 R132L。每种突变都可能导致不同肿瘤类型，具有不同恶性进展。最常见的突变（>90％）是精氨酸变为组氨酸（R132H）。 因此，识别 IDH1R132H 突变的抗体可用于诊断携带突变的肿瘤（如神经胶质瘤）。
Disclaimer
除非我们的产品目录或产品随附的其他公司文件中另有说明，否则我们的产品仅用于研究用途，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、体外或体内治疗用途或任何类型的人类或动物消费或应用。
General description
鼠抗IDH1（R132H）单克隆抗体（小鼠IgG1同种型）源自杂交瘤HMab1。这一杂交瘤是用对应人IDH1突变R132H 的多肽对 BALB/c 小鼠进行免疫接种后，取脾细胞与小鼠骨髓瘤细胞融合产生。异柠檬酸脱氢酶（IDH）家族成员IDH1是人细胞质NADP特异性酶。其亚细胞定位显示在过氧化物酶体和细胞质中。
Immunogen
与人 IDH1 突变 R132H 相对应的的肽。
Physical form
0.01M 磷酸缓冲盐溶液，pH 7.4，含 15mM 叠氮化钠。
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
此项目有
Shuchen Chen et al.
Cancer medicine, 11(22), 4122-4133 (2022-05-09)
Isocitrate dehydrogenase (IDH) is an appealing target for anticancer therapy, and IDH (IDH1/2) inhibitors have been approved for targeted therapy of acute myeloid leukemia (AML) and Cholangiocarcinoma. The therapeutic potential of IDH inhibitors for non-small-cell lung cancer (NSCLC) patients is
Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: the role of size and hydrophobicity at residue 132 on catalytic efficiency
Matteo D A, et al.
The Journal of biological chemistry, 292(19), 7971-7983 (2017)
Clinicopathological Analysis of HIF-1alpha and TERT on Survival Outcome in Glioblastoma Patients: A Prospective, Single Institution Study
Potharaju M, et al.
Journal of Cancer, 10(11), 2397-2406 (2019)
Bin Sheng Wong et al.
Nature biomedical engineering, 5(1), 26-40 (2020-09-30)
Clinical scores, molecular markers and cellular phenotypes have been used to predict the clinical outcomes of patients with glioblastoma. However, their clinical use has been hampered by confounders such as patient co-morbidities, by the tumoral heterogeneity of molecular and cellular
Yongying Gao et al.
Molecular medicine reports, 23(5) (2021-03-25)
Isocitrate dehydrogenase1 (IDH1) mutation is the most important genetic change in glioma. The most common IDH1 mutation results in the amino acid substitution of arginine 132 (Arg/R132), which is located at the active site of the enzyme. IDH1 Arg132His (R132H)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持